Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Monica Hellesøy
Observed names:
Hellesøy, Monica,
M. Hellesøy,
Monica Hellesoy
Institution:
Fonna Hospital Trust
Observed institutions:
Haukeland University Hospital,
Medizinische Hochschule Hannover,
BerGenBio (Norway),
Fonna Hospital Trust,
University of Bergen,
The University of Texas Southwestern Medical Center
show all 6
ORCID:
0000-0002-0115-7427
Observed ORCID:
0000-0002-0115-7427
OpenAlex ID:
A5000870281
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2021
·
Disha Malani
, Ashwini Kumar
, et al.
·
Cancer Discovery
·
212
PDF
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
2020
·
Maria L. Lotsberg
, Katarzyna Wnuk-Lipinska
, et al.
·
Journal of Thoracic Oncology
·
103
PDF
Efficient in vivo vascularization of tissue-engineering scaffolds
2010
·
Anja Hegen
, Anna Blois
, et al.
·
Journal of Tissue Engineering and Regenerative Medicine
·
68
PDF
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
2023
·
Benedicte Sjo Tislevoll
, Monica Hellesøy
, et al.
·
Nature Communications
·
35
PDF
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
2019
·
Muntasir M. Majumder
, Aino-Maija Leppä
, et al.
·
Haematologica
·
27
PDF
Titrating Complex Mass Cytometry Panels
2019
·
Stein‐Erik Gullaksen
, Lucius Bader
, et al.
·
Cytometry Part A
·
24
PDF
Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
2021
·
Monica Hellesøy
, Caroline Engen
, et al.
·
Molecular Oncology
·
23
PDF
FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
2021
·
Caroline Engen
, Monica Hellesøy
, et al.
·
Molecular Oncology
·
21
PDF
Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies
2014
·
Katarzyna Wnuk-Lipinska
, Crina Tiron
, et al.
·
Cancer Research
·
18
Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia
2019
·
Rakel Brendsdal Forthun
, Monica Hellesøy
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
12
PDF
Cellular context–mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis
2015
·
Monica Hellesøy
, James B. Lorens
·
Molecular Biology of the Cell
·
12
PDF
Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses
2021
·
Sonja Loges
, Grerk Sutamtewagul
, et al.
·
Blood
·
8
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.
2019
·
Sonja Loges
, Michael Heuser
, et al.
·
Journal of Clinical Oncology
·
8
Single Cell Detection of the p53 Protein by Mass Cytometry
2020
·
Oda Helen Eck Fagerholt
, Monica Hellesøy
, et al.
·
Cancers
·
7
PDF
Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy
2016
·
Gro Gausdal
, Kjersti Davidsen
, et al.
·
Cancer Research
·
7
Preclinical characterisation and development of a novel myelodysplastic syndrome‐derived cell line
2021
·
Sahba Shafiee
, Pascal Gelebart
, et al.
·
British Journal of Haematology
·
6
The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)
2020
·
Sonja Loges
, Michael Heuser
, et al.
·
Blood
·
6
Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
2023
·
Ida Vänttinen
, Tanja Ruokoranta
, et al.
·
Blood
·
5
Early response evaluation in AML using mass cytometry
2019
·
Bjørn T. Gjertsen
, Benedicte S. Tislevoll
, et al.
·
HemaSphere
·
4
Akt1 Activity Regulates Vessel Maturation in a Tissue Engineering Model of Angiogenesis
2014
·
Monica Hellesøy
, Anna L. Blois
, et al.
·
Tissue Engineering Part A
·
4
Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.
2014
·
Katarzyna Wnuk-Lipinska
, Gro Gausdal
, et al.
·
Clinical Cancer Research
·
4
Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry
2024
·
Dimitrios Kleftogiannis
, Sonia Gavasso
, et al.
·
iScience
·
3
Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy
2016
·
Gro Gausdal
, Kjersti Davidsen
, et al.
·
Cancer Immunology Research
·
3
A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy
2018
·
Benedicte Sjo Tislevoll
, Oda Helen Eck Fagerholt
, et al.
·
Blood
·
2
Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.
2018
·
Bjorn T. Gjertsen
, Monica Hellesøy
, et al.
·
Journal of Clinical Oncology
·
2
Show more works
View as search
Works count:
49
Citation count:
630
H-index:
11
I10-index:
11
Year
Topic
Type